British Patient Capital

Maxion Therapeutics develops a novel platform to generate antibody-like therapeutics targeting ion channels and GPCR-driven diseases. The platform incorporates venom-derived knottins into antibody surfaces to create mixtures with optimized drug-like properties, enabling treatments for conditions such as chronic pain, autoimmune disorders, and heart disease. The company aims to deliver long-acting, safe, and effective medications against previously inaccessible targets.

Quantexa develops a decision intelligence platform that unifies siloed data from various sources. Its solution provides a contextual, connected view of internal and external data to help organizations make trusted operational decisions, mitigate fraud risks, and uncover new opportunities. Established in 2016, Quantexa serves clients globally across financial services, corporate, and public sectors.

Cambridge GaN Devices develops gallium nitride based power devices and transistors designed to improve energy efficiency in power electronics. The company designs, creates, and commercializes GaN-based semiconductors that achieve faster switching, lower energy losses, and smaller form factors compared with traditional silicon devices while delivering higher power density. Its products are intended for applications in sectors such as renewable energy, electric vehicles, and consumer electronics, enabling compact and more efficient power conversion and energy management. The company collaborates with industry partners to drive innovation and accelerate adoption of GaN technology in the power semiconductor market.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

Tokamak Energy Ltd is a private company based in Abingdon, United Kingdom, focused on the development of fusion power technology. Founded in 2009, the company specializes in creating compact and cost-effective fusion power devices, particularly through the use of spherical tokamaks. These innovative reactors are designed to achieve higher plasma pressure with reduced magnetic field requirements compared to traditional tokamaks. Tokamak Energy utilizes high-temperature superconducting magnets to enhance plasma control within its devices, thereby improving efficiency. The company's commitment to rapid innovation leverages advanced materials and technology, building on decades of scientific research. By aiming to develop commercial fusion power solutions, Tokamak Energy contributes to the pursuit of affordable and sustainable energy, addressing global energy security while minimizing environmental impact.

Purespring Therapeutics specializes in developing gene therapies targeting kidney diseases, focusing on podocytes, specialized kidney cells. It is one of the first globally to use AAV gene therapy specifically for kidney conditions.

Form3 is a London-based company that provides cloud-based payment processing, clearing, and settlement services specifically designed for regulated financial institutions. Founded in 2016, it offers a fully managed payment technology service that leverages a robust AWS cloud processing platform and multiple payment gateways, ensuring 24/7 operational support. The company's micro-services architecture and application programming interfaces enable clients to access a wide array of payment schemes seamlessly. Form3's client base includes a diverse range of financial entities, such as leading banks, non-bank financial institutions, and fintech companies, including payment institutions and e-money providers. This innovative approach allows businesses to utilize reliable and secure payment services on a per-transaction commercial model without upfront costs.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

Wagestream Ltd., founded in 2018 and headquartered in London, United Kingdom, develops a financial services application designed to enhance employee benefits and financial well-being. The platform allows employees to access their earned wages instantly, providing them with greater control over their pay schedules. This innovation aims to alleviate financial stress related to unexpected expenses by eliminating the need for advances, loans, and the burdens of high-interest credit or payday loans. Additionally, Wagestream offers various financial tools that help businesses support their employees in managing expenses, setting savings goals, and developing financial plans. By addressing these financial challenges, Wagestream seeks to reduce the poverty premium and prevent employees from falling into cycles of debt.

Phagenesis develops a medical device for treating dysphagia, a swallowing disorder often resulting from stroke or brain injury. The device, Phagenyx, uses neurostimulation therapy to harness the brain's capacity for relearning lost functions via neuroplasticity. It consists of a base station and a catheter inserted through the nose, delivering optimal stimulations to the pharynx while recording patient data.

Curve Therapeutics Limited, established in 2019 and based in London, specializes in drug discovery with a focus on cancer. The company has developed an innovative screening platform that enables functional screening of diverse libraries against disease-associated targets within their native cellular environment. This platform is used to build a pipeline of novel cancer drugs targeting currently undruggable targets.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

OMass Therapeutics is a biotechnology company based in Oxford, United Kingdom, that leverages structural mass spectrometry to discover protein-based novel medicines. The company develops a platform that provides access to native mass spectrometry and enables the study of complex protein assemblies and their interactions with biomolecules, allowing biotechnology and pharmaceutical clients to tackle challenging drug targets and biotherapeutics. Through a collaborative framework, OMass Therapeutics supports drug discovery efforts by applying its mass spectrometry technology to identify and characterize potential therapeutic candidates without requiring clients to establish in-house instrumentation and expertise.

Quantexa develops a decision intelligence platform that unifies siloed data from various sources. Its solution provides a contextual, connected view of internal and external data to help organizations make trusted operational decisions, mitigate fraud risks, and uncover new opportunities. Established in 2016, Quantexa serves clients globally across financial services, corporate, and public sectors.

CyberSmart Ltd., established in 2016 and headquartered in London, specializes in designing and developing automated compliance software platforms. The company offers a suite of products, including Cyber Essentials, Cyber Essentials Plus, GDPR Ready, CyberSmart Platform, and certOS, which help businesses identify, secure, and certify security incidents. Its cloud-based dashboard manages the compliance process, while desktop applications deployed across networks monitor compliance status and detect non-conformities. Additionally, CyberSmart provides ongoing protection through regular security checks and cyber insurance coverage, targeting small to medium-sized businesses seeking to mitigate cyber threats and navigate evolving regulations.

Quantum Motion Technologies is developing a universal quantum computer using Silicon-based CMOS processes. Its focus lies in creating scalable arrays of qubits, aiming to develop quantum computing architectures compatible with existing silicon processing methods.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

Perspectum develops digital health technologies that support clinicians in diagnosing and treating liver disease, diabetes, and cancer. Leveraging precision medicine through advanced imaging and genetics, the company provides AI-driven imaging tools and quantitative health assessments to enable early detection, accurate diagnosis, and targeted therapies. Its software-as-a-service platform delivers disease mapping, quantitative reports, and access to proprietary datasets for AI training, assisting physicians in clinical decision-making and helping pharmaceutical developers advance therapeutic programs. The team includes physicians, biomedical scientists, engineers, and technologists, and Perspectum aims to scale management of complex health problems across healthcare systems.

Pragmatic is a developer of ultra-low-cost flexible integrated circuits, known as FlexICs, which are thinner than human hair and can be seamlessly embedded in various objects. This innovative technology allows designers to create application-specific flexible devices efficiently and at a fraction of the cost and time compared to traditional silicon circuits. Pragmatic also offers standard FlexIC products that enhance established applications like RFID and NFC, facilitating the creation of smart objects that can interact with consumers and their environments. The company's manufacturing is powered by the FlexLogIC production system, which enables cost-effective, high-volume production with significantly lower capital investments compared to conventional silicon fabrication methods. Pragmatic's technology is being increasingly adopted by a diverse range of global companies in markets such as consumer goods, retail, healthcare, pharmaceuticals, gaming, and security. Headquartered in Cambridge, UK, Pragmatic operates its first billion-unit production facility in Sedgefield.

Nucleome Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, founded in 2019. The company focuses on decoding the "dark matter" of the human genome, which comprises over 95% of disease-linked genetic variants that have not yet been fully explored. By leveraging a unique platform that creates high-resolution three-dimensional genome structure maps and employs machine learning techniques, Nucleome aims to link these genetic variants to gene functions and map disease pathways. This innovative approach facilitates the functional validation of variants in primary cell types, enabling the discovery and development of novel therapeutics. Initially concentrating on lymphocytes and autoimmune diseases, Nucleome Therapeutics seeks to establish a robust pipeline of drug assets along with corresponding biomarkers to improve patient outcomes through genetically guided therapeutics.

Oxford Quantum Circuits develops quantum computing technology, aiming to tackle complex challenges such as climate change and drug discovery. Their fully functional quantum computer system enables businesses to explore innovative solutions and address global issues.

CloudNC is a London-based software company that develops autonomous manufacturing software to automate the programming of computer numerical control milling machines. It provides software and cloud-based services to design tooling paths and streamline CNC programming, enabling factories to produce precision metal components with minimal human intervention. The company also offers an end-to-end manufacturing service intended to replace skilled human roles in metal part production, aiming to improve lead times, machine utilization, and scalability. Incorporated in 2015, CloudNC seeks to modernize manufacturing by making milling processes more efficient and predictable, supporting industries that rely on precision parts.

Proximie Inc., headquartered in Bedford, Massachusetts, operates a health technology platform that facilitates remote, real-time collaboration among surgeons worldwide. The company's core service enables surgeons to virtually attend operations via augmented reality, artificial intelligence, and machine learning technologies. This allows them to visually guide complex surgeries, demonstrate techniques, and provide expertise remotely, thereby democratizing access to advanced surgical knowledge globally. Founded by Nadine Hachach-Haram in 2016, Proximie aims to enhance surgical outcomes and improve patient care through innovative telehealth solutions.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing human microbiome-based therapeutics. Founded in 2016, the company operates a platform that identifies gut bacteria associated with specific phenotypes from clinical trial samples. This advanced platform allows researchers to pinpoint gut bacteria with high precision, facilitating the development of live bacterial therapeutics and biomarkers. By enabling the identification of phenotypes prior to testing candidate bacteria in sophisticated human in vitro and in vivo models, Microbiotica aims to advance the understanding and application of microbiome science in therapeutic contexts.

Thought Machine develops cloud-native technology to revolutionize core banking, aiming to address the industry's reliance on outdated IT infrastructure. Its flagship product, Vault, is a configurable retail banking platform built from scratch as a microservice API architecture.

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Ultraleap specializes in developing and commercializing innovative haptic control systems. Founded in 2013, the company is renowned for its mid-air haptics and 3D hand tracking technologies. Ultraleap's solutions include Leap Motion Controller for optical hand tracking, VR Developer Mount for virtual reality experiences, and Gemini, a hand tracking platform. Its applications span across extended reality, automotive, digital signage, industrial automation, consumer electronics, and location-based entertainment.

AccuRx is a healthcare communication platform that connects patients and medical professionals to streamline care. The platform enables SMS messaging, appointment reminders, referrals, patient surveys, and video consultations, and supports managing virtual wards, outpatient clinics, and follow-up pathways, helping to improve efficiency in primary care. Founded in 2016 and based in London, it is used by a large majority of GP practices and NHS trusts.

Quantexa develops a decision intelligence platform that unifies siloed data from various sources. Its solution provides a contextual, connected view of internal and external data to help organizations make trusted operational decisions, mitigate fraud risks, and uncover new opportunities. Established in 2016, Quantexa serves clients globally across financial services, corporate, and public sectors.

Thought Machine develops cloud-native technology to revolutionize core banking, aiming to address the industry's reliance on outdated IT infrastructure. Its flagship product, Vault, is a configurable retail banking platform built from scratch as a microservice API architecture.

Quantexa develops a decision intelligence platform that unifies siloed data from various sources. Its solution provides a contextual, connected view of internal and external data to help organizations make trusted operational decisions, mitigate fraud risks, and uncover new opportunities. Established in 2016, Quantexa serves clients globally across financial services, corporate, and public sectors.